Tilak Healthcare, a French manufacturer of digital devices used to monitor chronic retina diseases, recently announced positive results from a clinical trial of OdySight, a mobile app that allows patients to measure their visual acuity at home.

OdySight is a prescription-only CE-marked medical device available on smartphones and tablets that allows patients with chronic macular degeneration to carry out regular monitoring of their visual acuity through eye tests that they perform themselves. Results are sent automatically to their physicians along with notifications when a deterioration in vision is detected. This makes monitoring between appointments easier and facilitates medical intervention where necessary. Since 2022, the OdySight app has been prescribed to more than 15,000 patients in France.

The TIL002 study, conducted at three French hospitals and involving 58 patients and 105 eyes, showed a high level of convergence between at-home evaluations of visual acuity measured with OdySight and standard methods used during patient appointments, reported Dr. Jean-François Girmens, medical director and cofounder of Tilak Healthcare.